Psyence Biomedical Ltd. (NASDAQ:PBM) Short Interest Update

Psyence Biomedical Ltd. (NASDAQ:PBM) saw a significant decrease in short interest in the month of February. As of February 13th, there was short interest totaling 86,725 shares, a decrease of 40.4% from the January 29th total of 145,422 shares. Approximately 8.8% of the company’s shares are short sold. Based on an average daily volume of 657,517 shares, the short-interest ratio is presently 0.1 days. Based on an average daily volume of 657,517 shares, the short-interest ratio is presently 0.1 days. Approximately 8.8% of the company’s shares are short sold.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Psyence Biomedical in a report on Thursday, January 22nd. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Psyence Biomedical presently has an average rating of “Sell”.

Psyence Biomedical Stock Up 0.8%

Psyence Biomedical stock traded up $0.02 during midday trading on Monday, reaching $2.56. The company’s stock had a trading volume of 22,334 shares, compared to its average volume of 533,720. The company has a market cap of $2.61 million, a P/E ratio of 0.10 and a beta of 0.36. The business has a 50-day simple moving average of $4.00 and a 200-day simple moving average of $12.89. Psyence Biomedical has a fifty-two week low of $1.92 and a fifty-two week high of $74.94.

Institutional Trading of Psyence Biomedical

A hedge fund recently bought a new stake in Psyence Biomedical stock. Virtu Financial LLC acquired a new position in shares of Psyence Biomedical Ltd. (NASDAQ:PBM) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 10,325 shares of the company’s stock, valued at approximately $33,000. Virtu Financial LLC owned about 0.55% of Psyence Biomedical at the end of the most recent quarter. Hedge funds and other institutional investors own 77.44% of the company’s stock.

Psyence Biomedical Company Profile

Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company’s lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care.